465 related articles for article (PubMed ID: 24818801)
1. NMDA antagonists under investigation for the treatment of major depressive disorder.
Pochwat B; Pałucha-Poniewiera A; Szewczyk B; Pilc A; Nowak G
Expert Opin Investig Drugs; 2014 Sep; 23(9):1181-92. PubMed ID: 24818801
[TBL] [Abstract][Full Text] [Related]
2. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
Preskorn S; Macaluso M; Mehra DO; Zammit G; Moskal JR; Burch RM;
J Psychiatr Pract; 2015 Mar; 21(2):140-9. PubMed ID: 25782764
[TBL] [Abstract][Full Text] [Related]
3. Glutamate-based antidepressants: 20 years on.
Skolnick P; Popik P; Trullas R
Trends Pharmacol Sci; 2009 Nov; 30(11):563-9. PubMed ID: 19837463
[TBL] [Abstract][Full Text] [Related]
4. Investigational NMDA receptor modulators for depression.
Szewczyk B; Pałucha-Poniewiera A; Poleszak E; Pilc A; Nowak G
Expert Opin Investig Drugs; 2012 Jan; 21(1):91-102. PubMed ID: 22097925
[TBL] [Abstract][Full Text] [Related]
5. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB;
Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481
[TBL] [Abstract][Full Text] [Related]
6. An update on NMDA antagonists in depression.
Pochwat B; Nowak G; Szewczyk B
Expert Rev Neurother; 2019 Nov; 19(11):1055-1067. PubMed ID: 31328587
[No Abstract] [Full Text] [Related]
7. Targeting of NMDA receptors in the treatment of major depression.
Dang YH; Ma XC; Zhang JC; Ren Q; Wu J; Gao CG; Hashimoto K
Curr Pharm Des; 2014; 20(32):5151-9. PubMed ID: 24410564
[TBL] [Abstract][Full Text] [Related]
8. [Antidepressant effect of ketamine, a N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, in the therapy of treatment-resistant depression].
Gosek P; Chojnacka M; Bieńkowski P; Swiecicki Ł
Psychiatr Pol; 2012; 46(2):283-94. PubMed ID: 23214398
[TBL] [Abstract][Full Text] [Related]
9. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists.
Moskal JR; Burch R; Burgdorf JS; Kroes RA; Stanton PK; Disterhoft JF; Leander JD
Expert Opin Investig Drugs; 2014 Feb; 23(2):243-54. PubMed ID: 24251380
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.
Jaso BA; Niciu MJ; Iadarola ND; Lally N; Richards EM; Park M; Ballard ED; Nugent AC; Machado-Vieira R; Zarate CA
Curr Neuropharmacol; 2017; 15(1):57-70. PubMed ID: 26997505
[TBL] [Abstract][Full Text] [Related]
11. How does ketamine elicit a rapid antidepressant response?
Kavalali ET; Monteggia LM
Curr Opin Pharmacol; 2015 Feb; 20():35-9. PubMed ID: 25462290
[TBL] [Abstract][Full Text] [Related]
12. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.
Sos P; Klirova M; Novak T; Kohutova B; Horacek J; Palenicek T
Neuro Endocrinol Lett; 2013; 34(4):287-93. PubMed ID: 23803871
[TBL] [Abstract][Full Text] [Related]
13. Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression.
Drewniany E; Han J; Hancock C; Jones RL; Lim J; Nemat Gorgani N; Sperry JK; Yu HJ; Raffa RB
J Clin Pharm Ther; 2015 Apr; 40(2):125-30. PubMed ID: 25545040
[TBL] [Abstract][Full Text] [Related]
14. The "blue" side of glutamatergic neurotransmission: NMDA receptor antagonists as possible novel therapeutics for major depression.
Szakacs R; Janka Z; Kalman J
Neuropsychopharmacol Hung; 2012 Mar; 14(1):29-40. PubMed ID: 22427468
[TBL] [Abstract][Full Text] [Related]
15. Glutamate-Based Drug Discovery for Novel Antidepressants.
Pałucha-Poniewiera A; Pilc A
Expert Opin Drug Discov; 2016 Sep; 11(9):873-83. PubMed ID: 27409299
[TBL] [Abstract][Full Text] [Related]
16. Investigational drugs for treating major depressive disorder.
Dhir A
Expert Opin Investig Drugs; 2017 Jan; 26(1):9-24. PubMed ID: 27960559
[TBL] [Abstract][Full Text] [Related]
17. Targeting glutamate signalling in depression: progress and prospects.
Murrough JW; Abdallah CG; Mathew SJ
Nat Rev Drug Discov; 2017 Jul; 16(7):472-486. PubMed ID: 28303025
[TBL] [Abstract][Full Text] [Related]
18. The role of glutamate on the action of antidepressants.
Hashimoto K
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
[TBL] [Abstract][Full Text] [Related]
19. Ketamine: The final frontier or another depressing end?
Sial OK; Parise EM; Parise LF; Gnecco T; Bolaños-Guzmán CA
Behav Brain Res; 2020 Apr; 383():112508. PubMed ID: 32017978
[TBL] [Abstract][Full Text] [Related]
20. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
